Cannabis has long been known to cause a range of mental health issues, including hallucinations, mood changes, amnesia, depersonalization, paranoia, delirium and disorientation. However, recent research has suggested that cannabidiol (CBD) may have the potential to reduce the symptoms of psychosis. CBD is a phytocannabinoid found in cannabis plants and is one of the most prevalent cannabinoids. It interacts with the body through the endocannabinoid system to alter the release of neurotransmitters in the brain, altering mood, appetite and pain response.
Unlike THC, which activates CB1 receptors in the brain and can cause a sense of euphoria, CBD is a CB1 receptor antagonist and will never cause the “high” commonly associated with cannabis use. Studies have shown that CBD can reduce brain activity related to hallucinations, delusions and other forms of psychosis. In addition, it has been found to improve functional and cognitive abilities in patients who received a single dose of CBD compared to those who received placebo. However, it is important to note that CBD was only given as a complementary treatment in most studies; and all participants continued to receive their conventional antipsychotic treatment.
To understand the potential benefit of CBD as a stand-alone treatment for psychosis, more research is needed. Researchers at King's College are now launching the first large-scale trial to investigate whether pure medical-grade CBD is an effective treatment for young people who are at high risk of developing psychosis. The results of this trial could provide valuable insight into the potential benefits of CBD for those suffering from psychotic symptoms.
